After a wave of feedback, the accreditor has deferred a ban on use of corporate logos in disclosures of commercial support.
The accreditor wants comments on its new accreditation plan, but a new commendation proposal is yet to come.
Some providers of CME are getting better at complying with accreditation criteria, data show, yet many are still struggling to meet a stricter set of requirements.
Pharma's med-ed cut was its fifth in a row. But other income surged, filling the void as the funding picture for CME continued to even out.
With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
The estimated cost savings for only 10% of participants changing their practice is somewhere in the million-dollar range, according to a study.
The drug industry dialed back its continuing medical education (CME) grant-giving in 2011, continuing a negative trend of the last few years.
The FDA's opioid REMS safety plan is challenged on two fronts: getting CME providers to offer courses and getting doctors to attend them. Can the agency's scheme educate enough physicians to curb an epidemic?
Doctors are still getting their CME, but mostly the non-commercially supported kind.
State-accredited CME providers continue to decrease, with 68 dropping out as of last year, but so far the trend has not posed a threat to physician education, one official says.
Corporate logos may still appear in CME commercial support disclosures, ACCME said, after a majority of respondents expressed disapproval of its proposal to ban them.
The drug industry's backing of certified CME fell for a third straight year, as registration fees and other income surged, just-released data from ACCME show.
A new report passed by AMA delegates draws ethical boundaries around the use of industry funding for medical education, stopping well short of the all-out ban seen in some previous versions.
The American Board of Medical Specialties (ABMS) issued a white paper examining how CME can support its Maintenance of Certification (MOC) requirement in the future. The paper raised hackles among some who saw it as a call for new credit systems.
The non-profit group that regulates CME said providers must issue corrected information if an activity is found noncompliant.
A new medical education company has opened offering to produce CME that is free of commercial support.
At a recent FDA advisory hearing on ways to increase the safety of extended-release and long-acting opioid drugs, the agency opened the door to using continuing medical education (CME) to help reach the goal.
Total commercial support of accredited CME fell 17% to $856 million in 2009, according to ACCME's annual report—marking its second straight year of double-digit declines on a percentage basis.
ACCME: Peer review, plus other provider controls, enable industry employees to present original research in CMEJune 29, 2010
Several months' worth of dialogue, at times public and heated, between physician groups like the American Heart Association and the ACCME, has resulted in new guidance from the regulator of continuing medical education: Industry scientists, who had been barred from presenting original product-related research at for-credit talks, may now do so as long as provider controls ensure they have zero control over the content.
The number of providers placed on probation by the nonprofit that regulates continuing medical education has more than doubled this year, from 15 to 35.
A policy barring pharmaceutical industry employees from giving continuing medical education talks at meetings has elicited strong opposition from physician leaders.
Comments to a recent ACCME proposal formed a clear consensus: Accredited med-ed providers who break the rules should not be identified, unless changes in their accreditation status occur.
Medical society journals must ban ghostwritten articles and cannot place ads for drugs next to editorial content discussing those products or their makers under a sweeping ethics code signed by several major medical societies.
The ACCME said it will consider releasing names of providers and activities found to violate bias rules. The exact details of the disclosure, if any, and the timing are under review by the ACCME Board of Directors, which meets December 3-4.
Total commercial support of accredited CME dropped 14% to $1 billion in 2008, according to the Accreditation Council for Continuing Medical Education's annual report -- even as the number of physicians participating in CME activities jumped 22% to 10.6 million.
Certified and accredited CME has undergone a sea-change in recent years, with policies now in place emphasizing quality and leaving little room for bias (not that you'd know it, for all the buzz about conflicts of interest)
Featuring news about the ACCME, the Association for Clinical Researchers and Educators, SACME and the Association of American Medical Colleges
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.